# Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder

> **NCT01228370** · PHASE4 · COMPLETED · sponsor: **JW Pharmaceutical** · enrollment: 95 (actual)

## Conditions studied

- Neurogenic Bladder
- Voiding Dysfunction

## Interventions

- **DRUG:** silodosin

## Key facts

- **NCT ID:** NCT01228370
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2012-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01228370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01228370, "Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01228370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*